Enoxaparin Sodium Injection, USP is used for prophylaxis of Deep Vein Thrombosis (DVT) in patients undergoing abdominal, hip or knee replacement surgery, and also for the treatment of acute DVT
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
With this commissioning, Shilpa Medicare joins a very small group of Indian companies capable of offering end-to-end ADC Drug Substance development and manufacturing
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Veteran health innovation and policy leader to drive biotechnology innovation, startup growth and commercialization of indigenous technologies
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
